Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Picard Medical Q3 2026 Results: Net Loss of $2.22M, Loss Narrows

Picard Medical, Inc. is a newly public medical device company focused on total artificial heart therapy, reporting 2,661,574 shares outstanding as of November 12, 2026. The filing highlights significant risks including customer concentration, reliance on single-source suppliers, and an explanatory paragraph from its auditors regarding its ability to continue as a going concern.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue0.21.2
Gross profit0.1-0.1
Profit before tax-2.2-10.4
Net income-2.2-10.4
EPS (diluted, $ a share)$-0.95$-9.57

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-81.7%
Gross margin43.8%
Source

10-Q filed with the SEC, NYSE: PMI. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Picard Medical, Inc.: key numbers

Share price
$7.24Close, Nov 16
Market cap
$19.3M
Shares outstanding
2.66MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Picard Medical, Inc.

All →
5:22 PM ET 8-K
Leadership Change

Picard Medical Leadership Change

Picard Medical, Inc. appointed Richard Fang, Ph.D., as its permanent Chief Executive Officer, effective October 28, 2026. Dr. Fang, who has served as Interim CEO since June 2024 and is the current Chairman of the Board, will receive an annual salary of $0.4 million with no new compensation awards granted at this time.

4:51 PM ET 8-K
Other 8-K Filing

Picard Medical Other 8-K Filing

Picard Medical entered into a Warrant Amendment and Exchange Agreement to issue 200,000 shares of common stock in exchange for the surrender and cancellation of existing warrants. The transaction was conducted as a debt-free exchange under Section 3(a)(9) of the Securities Act, effectively discharging all anti-dilution and adjustment rights associated with the original warrants.

12:35 PM ET 8-K
Loan & Debt

Picard Medical $1M Debt Financing with three accredited investors

Picard Medical, Inc. issued three unsecured convertible notes in the aggregate principal amount of $1.0 million to three accredited investors. The notes bear 3.0% interest and mature on September 30, 2027, with a conversion floor price of $4.00 per share. Upon conversion, the company will also issue pre-funded warrants to the holders on a one-for-one basis.

Value
$1M
Counterparty
three accredited investors
Term
1 year

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.